Solace Pharmaceuticals has closed its Cambridge, MA-based office following disappointing results from a Phase II trial of its pain treatment pill SLC022. The company was founded in 2006 and has so far raised $15 million in capital. Solace's four remaining full-time employees are based out the company's office in Canterbury, U.K. Report